AngioDynamics Stock Price, News & Analysis (NASDAQ:ANGO)

AngioDynamics trades on the NASDAQ under the ticker symbol "ANGO."

AngioDynamics, Inc. (NASDAQ:ANGO) announced its quarterly earnings data on Wednesday, July, 10th. The medical instruments supplier reported $0.25 EPS for the quarter, missing the Zacks' consensus estimate of $0.26 by $0.01. The medical instruments supplier had revenue of $96.30 million for the quarter, compared to analyst estimates of $92.34 million. AngioDynamics had a return on equity of 5.58% and a net margin of 17.06%. The business's quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.20 earnings per share. View AngioDynamics' Earnings History.

AngioDynamics is scheduled to release their next quarterly earnings announcement on Thursday, October 3rd 2019. View Earnings Estimates for AngioDynamics.

AngioDynamics will be holding an earnings conference call on Thursday, October 3rd at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

AngioDynamics issued an update on its FY20 earnings guidance on Wednesday, July, 10th. The company provided EPS guidance of $0.25-0.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $280.90 million.

1 brokerages have issued 12-month price targets for AngioDynamics' stock. Their predictions range from $23.00 to $23.00. On average, they expect AngioDynamics' share price to reach $23.00 in the next year. This suggests a possible upside of 19.5% from the stock's current price. View Analyst Price Targets for AngioDynamics.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for AngioDynamics.

News coverage about ANGO stock has been trending somewhat negative on Saturday, according to InfoTrie. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. AngioDynamics earned a news sentiment score of -1.3 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for AngioDynamics.

AngioDynamics saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 1,409,300 shares, an increase of 10.2% from the July 31st total of 1,279,100 shares. Based on an average daily volume of 195,700 shares, the short-interest ratio is presently 7.2 days. Currently, 3.9% of the shares of the stock are sold short. View AngioDynamics' Current Options Chain.

Some companies that are related to AngioDynamics include Nevro (NVRO), Glaukos (GKOS), Irhythm Technologies (IRTC), Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Cryolife (CRY), Silk Road Medical (SILK), Luminex (LMNX), AtriCure (ATRC), Tactile Systems Technology (TCMD), Orthofix Medical (OFIX), Shockwave Medical (SWAV), Axonics Modulation Technologies (AXNX) and Anika Therapeutics (ANIK).

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include Oasis Petroleum (OAS), General Electric (GE), Intel (INTC), Mattel (MAT), Chesapeake Energy (CHK), Centurylink (CTL), DIGITAL RLTY TR/SH (DLR), Hanesbrands (HBI), Kimco Realty (KIM) and Regions Financial (RF).

AngioDynamics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.72%), Victory Capital Management Inc. (10.12%), Vanguard Group Inc. (6.16%), Janus Henderson Group PLC (3.28%), Janus Henderson Group PLC (3.28%) and Northern Trust Corp (3.16%). Company insiders that own AngioDynamics stock include Kevin J Gould and Michael Greiner. View Institutional Ownership Trends for AngioDynamics.

ANGO stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, JPMorgan Chase & Co., THB Asset Management, Renaissance Technologies LLC, Invesco Ltd., AXA, Janus Henderson Group PLC and Janus Henderson Group PLC. Company insiders that have sold AngioDynamics company stock in the last year include Kevin J Gould and Michael Greiner. View Insider Buying and Selling for AngioDynamics.

ANGO stock was bought by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Systematic Financial Management LP, Nuveen Asset Management LLC, Price T Rowe Associates Inc. MD, Marshall Wace North America L.P., BlackRock Inc., Morgan Stanley and Natixis Advisors L.P.. View Insider Buying and Selling for AngioDynamics.

Shares of ANGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ANGO stock can currently be purchased for approximately $19.25.

AngioDynamics has a market capitalization of $720.91 million and generates $359.48 million in revenue each year. The medical instruments supplier earns $61.34 million in net income (profit) each year or $0.83 on an earnings per share basis. AngioDynamics employs 1,050 workers across the globe.View Additional Information About AngioDynamics.

The official website for AngioDynamics is http://www.angiodynamics.com/.

AngioDynamics' mailing address is 14 PLAZA DRIVE, LATHAM NY, 12110. The medical instruments supplier can be reached via phone at 518-795-1400 or via email at [email protected]